Depressed by three factors, the export growth of traditional Chinese medicine in the first half of the year rarely fell below 10%.

Affected by rising costs, fluctuations in prices of medicinal herbs, and policy factors, traditional Chinese medicines with relatively good exports have seen a relatively modest slowdown in the first half of this year. Yesterday, the reporter learned from the China Chamber of Commerce for the Import and Export of Medicines and Health Products (hereinafter referred to as the “Medical Insurance Chamber of Commerce”) that the total import and export volume of Chinese medicine in the previous June was US$1.6 billion, an increase of 11.2% year-on-year and 30 percentage points lower than the same period of last year; the export value was US$1.2 billion, a year-on-year increase of 9.6%, a decrease of 33% from the same period last year.

The Medical Insurance Association particularly emphasized that since the beginning of the new century, the export of Chinese medicine has been booming, with most of the increase exceeding 20%. Even during the global financial crisis of 2008-2009, the export of Chinese medicines has maintained an increase of over 10%. Therefore, only 9.6% of the increase in export value in the first half of this year had to arouse the vigilance of the industry, and the export situation of Chinese medicine in the second half is still not optimistic.

From the analysis of specific influencing factors, the rise in raw material prices and the increase in labor costs have made the companies overwhelmed. In addition, the current difficulties of using loans for SMEs and spending money are very prominent, and the ability of exporting companies to accept orders has been weakened. In fact, the loss of cost advantages has forced many industries in China to be forced out of the international market. For the first half of the year, plant extracts occupying half of China's exports are facing severe challenges.

In addition, price fluctuations in Chinese herbal medicines have also made it difficult for Chinese medicine exports. As we all know, the main raw material for Chinese medicine is Chinese herbal medicine. However, affected by natural disasters, Chinese herbal medicines prices have continued to rise in recent years, and some varieties have been experiencing abnormally high price fluctuations due to hot money speculation. This has completely exceeded market expectations, and has caused great impact on Chinese medicine production and export enterprises. Enterprises have not dared to sign foreign trade orders. contract.

Also worth noting is policy adjustment. At the beginning of the year, the General Administration of Quality Supervision, Inspection and Quarantine and the General Administration of Customs jointly adjusted the Entry and Exit Commodity Catalogue for Inspection and Quarantine by Entry-Exit Inspection and Quarantine Institutions (2012) and received extensive attention from the plant extract industry. Even more suddenly faced with regulatory adjustments and penalties, many vegetative companies do not know how to deal with them. They can only voluntarily cancel orders or choose export codes with lower tax rebates.

The Medical Insurance Association recommends that in order to ensure a stable growth of exports, in the current situation of the overall situation of foreign trade and exports is not good, the government should carefully launch policies affecting foreign trade exports, so as not to injure the industry and enterprises.